NZ610034A - Prevention of adverse effects caused by cd3 specific binding domains - Google Patents

Prevention of adverse effects caused by cd3 specific binding domains

Info

Publication number
NZ610034A
NZ610034A NZ610034A NZ61003411A NZ610034A NZ 610034 A NZ610034 A NZ 610034A NZ 610034 A NZ610034 A NZ 610034A NZ 61003411 A NZ61003411 A NZ 61003411A NZ 610034 A NZ610034 A NZ 610034A
Authority
NZ
New Zealand
Prior art keywords
prevention
specific binding
adverse effects
binding domains
effects caused
Prior art date
Application number
NZ610034A
Other languages
English (en)
Inventor
Gerhard Zugmaier
Dirk Nagorsen
Juergen Scheele
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45044532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ610034(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of NZ610034A publication Critical patent/NZ610034A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Adhesives Or Adhesive Processes (AREA)
NZ610034A 2010-11-10 2011-10-27 Prevention of adverse effects caused by cd3 specific binding domains NZ610034A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41222910P 2010-11-10 2010-11-10
PCT/EP2011/068862 WO2012062596A1 (en) 2010-11-10 2011-10-27 Prevention of adverse effects caused by cd3 specific binding domains

Publications (1)

Publication Number Publication Date
NZ610034A true NZ610034A (en) 2015-05-29

Family

ID=45044532

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ610034A NZ610034A (en) 2010-11-10 2011-10-27 Prevention of adverse effects caused by cd3 specific binding domains

Country Status (32)

Country Link
US (2) US10130638B2 (enExample)
EP (3) EP3228315B1 (enExample)
JP (2) JP6023717B2 (enExample)
KR (1) KR101891845B1 (enExample)
CN (2) CN108403702A (enExample)
AU (3) AU2011328393B2 (enExample)
CA (1) CA2816668C (enExample)
CL (1) CL2013001287A1 (enExample)
CR (1) CR20130278A (enExample)
CY (1) CY1118894T1 (enExample)
DK (1) DK2637670T4 (enExample)
EA (1) EA026075B1 (enExample)
ES (2) ES2627538T5 (enExample)
FI (1) FI2637670T4 (enExample)
HR (1) HRP20170814T4 (enExample)
HU (1) HUE032782T2 (enExample)
IL (2) IL226268B (enExample)
LT (1) LT2637670T (enExample)
MA (1) MA34726B1 (enExample)
ME (1) ME02722B (enExample)
MY (1) MY173177A (enExample)
NZ (1) NZ610034A (enExample)
PH (1) PH12013500940A1 (enExample)
PL (1) PL2637670T5 (enExample)
PT (1) PT2637670T (enExample)
RS (1) RS55995B2 (enExample)
SG (2) SG10201508789TA (enExample)
SI (1) SI2637670T2 (enExample)
SM (1) SMT201700250T1 (enExample)
TN (1) TN2013000250A1 (enExample)
UA (1) UA113397C2 (enExample)
WO (1) WO2012062596A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114115A1 (de) 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
MY173177A (en) 2010-11-10 2020-01-02 Amgen Res Munich Gmbh Prevention of adverse effects caused by cd3 specific binding domains
WO2012146394A1 (en) * 2011-04-28 2012-11-01 Amgen Research (Munich) Gmbh Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
EP3620473A1 (en) 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
EP2951203B1 (en) * 2013-03-15 2019-05-22 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3736292B1 (en) 2013-12-17 2024-05-08 Genentech, Inc. Anti-cd3 antibodies and methods of use
KR20230022270A (ko) 2014-03-28 2023-02-14 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
KR20170066421A (ko) 2014-09-12 2017-06-14 제넨테크, 인크. 항-cll-1 항체 및 면역접합체
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CU24597B1 (es) 2014-11-26 2022-05-11 Xencor Inc Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
AR102918A1 (es) 2014-12-05 2017-04-05 Genentech Inc Anticuerpos anti-cd79b y métodos de uso
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
WO2016205200A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cll-1 antibodies and methods of use
PL3310814T3 (pl) 2015-06-16 2023-12-11 F. Hoffmann-La Roche Ag Humanizowane i wykazujące dojrzałe powinowactwo przeciwciała przeciwko FcRH5 i sposoby stosowania
CA2991799A1 (en) 2015-07-15 2017-01-19 Zymeworks Inc. Drug-conjugated bi-specific antigen-binding constructs
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN106810610A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
CN106810611A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US10781264B2 (en) 2016-02-03 2020-09-22 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
EP4050032A1 (en) 2016-06-28 2022-08-31 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR102562519B1 (ko) 2016-10-14 2023-08-02 젠코어 인코포레이티드 IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
KR20190104528A (ko) * 2016-12-03 2019-09-10 주노 쎄러퓨티크스 인코퍼레이티드 Car-t 세포들 투여를 결정하는 방법
KR20180090600A (ko) 2017-02-03 2018-08-13 주식회사 대유위니아 전기밥솥
ES2988795T3 (es) 2017-02-27 2024-11-21 Juno Therapeutics Inc Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular
EP3409322A1 (en) * 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
EP3645122A1 (en) 2017-06-30 2020-05-06 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
EP3676402B1 (en) * 2017-08-30 2023-12-27 Bristol-Myers Squibb Company A method to monitor pharmacodynamic responses mediated by in vivo administration of glucocorticoids
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CN112272563A (zh) 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
SG11202007390YA (en) 2018-02-08 2020-08-28 Genentech Inc Bispecific antigen-binding molecules and methods of use
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
EP3930850A1 (en) 2019-03-01 2022-01-05 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
CN120775051A (zh) 2019-05-21 2025-10-14 诺华股份有限公司 Cd19结合分子及其用途
RU2738802C1 (ru) * 2019-08-21 2020-12-17 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
EP4072584B1 (en) 2019-12-13 2026-01-28 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
CA3196076A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
US12516118B2 (en) 2020-11-04 2026-01-06 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies and anti-CD79b antibody drug conjugates
MX2023005132A (es) 2020-11-04 2023-05-25 Genentech Inc Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
US20250074981A1 (en) * 2021-04-06 2025-03-06 Memorial Sloan-Kettering Cancer Center Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
WO2023057650A1 (en) 2021-10-10 2023-04-13 Centre Hospitalier Universitaire Vaudois (Chuv) A method for predicting side effects of drugs and vaccines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
WO1999054440A1 (en) 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
US20070224191A1 (en) 2002-12-05 2007-09-27 Pdl Biopharma, Inc. Methods of treatment of Ulcerative Colitis and Crohn's disease with anti-CD3 antibodies
RU2005141512A (ru) 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
WO2006114115A1 (de) 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
CN101331151A (zh) 2005-12-16 2008-12-24 麦克罗梅特股份公司 治疗肿瘤性疾病的方式和方法
EP1976886B1 (en) 2005-12-16 2014-12-17 Amgen Research (Munich) GmbH Means and methods for the treatment of tumorous diseases
KR101589759B1 (ko) 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 ｃｄ３―입실론 결합 도메인
EP3461842A1 (en) 2007-04-03 2019-04-03 Amgen Research (Munich) GmbH Cross-species-specific binding domain
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
JP5647132B2 (ja) * 2008-11-07 2014-12-24 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 急性リンパ芽球性白血病の治療
SG179204A1 (en) * 2009-10-27 2012-04-27 Micromet Ag Dosage regimen for administering a cd19xcd3 bispecific antibody
HUE048639T2 (hu) 2010-10-27 2020-08-28 Amgen Res Munich Gmbh Eljárás DLBCL kezelésére
MY173177A (en) 2010-11-10 2020-01-02 Amgen Res Munich Gmbh Prevention of adverse effects caused by cd3 specific binding domains

Also Published As

Publication number Publication date
ES2627538T3 (es) 2017-07-28
LT2637670T (lt) 2017-05-25
JP6023717B2 (ja) 2016-11-09
SG190174A1 (en) 2013-07-31
SI2637670T1 (sl) 2017-06-30
JP2014504272A (ja) 2014-02-20
EA201390621A1 (ru) 2014-05-30
CA2816668C (en) 2021-03-23
EP3228315A1 (en) 2017-10-11
SI2637670T2 (sl) 2024-06-28
US20190142846A1 (en) 2019-05-16
HRP20170814T1 (hr) 2017-08-11
UA113397C2 (xx) 2017-01-25
PL2637670T3 (pl) 2017-08-31
FI2637670T4 (fi) 2024-03-19
ES2842937T3 (es) 2021-07-15
AU2018200915A1 (en) 2018-03-01
RS55995B1 (sr) 2017-09-29
EA026075B1 (ru) 2017-02-28
CA2816668A1 (en) 2012-05-18
SMT201700250T1 (it) 2017-07-18
JP2016193932A (ja) 2016-11-17
EP2637670A1 (en) 2013-09-18
ES2627538T5 (es) 2024-12-02
IL257164A (en) 2018-03-29
EP3228315B1 (en) 2020-11-25
MA34726B1 (fr) 2013-12-03
IL257164B (en) 2020-01-30
PT2637670T (pt) 2017-05-18
PL2637670T5 (pl) 2024-06-10
AU2011328393B2 (en) 2017-01-05
MY173177A (en) 2020-01-02
IL226268B (en) 2018-02-28
AU2011328393A1 (en) 2013-05-23
AU2017202079A1 (en) 2017-04-20
CN103533943B (zh) 2018-02-13
CN108403702A (zh) 2018-08-17
HRP20170814T4 (hr) 2024-05-10
DK2637670T3 (en) 2017-06-19
CN103533943A (zh) 2014-01-22
IL226268A0 (en) 2013-07-31
EP3831386A1 (en) 2021-06-09
KR101891845B1 (ko) 2018-08-24
EP2637670B2 (en) 2024-03-13
KR20140008313A (ko) 2014-01-21
AU2017202079B2 (en) 2017-11-30
CL2013001287A1 (es) 2014-02-21
US10130638B2 (en) 2018-11-20
JP6189491B2 (ja) 2017-08-30
AU2018200915B2 (en) 2019-09-19
DK2637670T4 (da) 2024-03-25
WO2012062596A1 (en) 2012-05-18
US20130287774A1 (en) 2013-10-31
TN2013000250A1 (en) 2014-11-10
HUE032782T2 (en) 2017-10-30
CY1118894T1 (el) 2018-01-10
SG10201508789TA (en) 2015-11-27
EP2637670B1 (en) 2017-03-08
CR20130278A (es) 2013-09-20
PH12013500940A1 (en) 2013-07-08
US11633408B2 (en) 2023-04-25
ME02722B (me) 2017-10-20
RS55995B2 (sr) 2024-04-30

Similar Documents

Publication Publication Date Title
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
WO2013063120A3 (en) Nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
AU2011328009A8 (en) Compounds and methods for treating pain
MX2011007930A (es) Conjugados de insulina cristalina.
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
WO2011090270A3 (ko) 오스모틴을 포함하는 신경질환의 예방 및 치료용 조성물
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
WO2012006585A3 (en) Use of interleukin-15 to treat cardiovascular diseases
MX2009011214A (es) Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)- 5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales.
UA59517U (ru) Фармацевтическая композиция для лечения больных опиоидной зависимостью

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2016 BY SHELSTON IP

Effective date: 20150902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2017 BY CPA GLOBAL

Effective date: 20160916

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2018 BY CPA GLOBAL

Effective date: 20170914

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2019 BY CPA GLOBAL

Effective date: 20180913

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2020 BY CPA GLOBAL

Effective date: 20190912

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2021 BY CPA GLOBAL

Effective date: 20200911

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2022 BY CPA GLOBAL

Effective date: 20210910

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2023 BY ANAQUA SERVICES

Effective date: 20220922

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2024 BY ANAQUA SERVICES

Effective date: 20230921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2025 BY ANAQUA SERVICES

Effective date: 20240920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2026 BY ANAQUA SERVICES

Effective date: 20250924